Remove Containment Remove Development Remove Sales
article thumbnail

Kite and Arcellx enter partnership for multiple myeloma therapy development

Pharmaceutical Technology

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Additionally, Kite will make other potential payments to Arcellx.

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product. Manager of Regulatory Compliance.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gilead wins patent battle with US government over HIV PrEP drugs

Pharmaceutical Technology

This marks a significant development in a tumultuous dispute between the pharmaceutical company and the US government. This research dates to the mid-2000s when CDC scientists developed the PrEP regimen, argued the government. While both Descovy and Truvada contain emtricitabine, they feature different forms of the antiviral tenofovir.

Drugs 264
article thumbnail

Expert Insights: Development and Manufacture of Highly Potent Oral Liquids

XTalks

In 2020, the US Food and Drug Administration (FDA) issued a Guidance for Industry recommending that sponsors include plans for developing age-appropriate formulations of drug products in instances where adult formulations may not be suitable for paediatric patients.

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX. Already a big player in haemophilia treatments, CSL licensed exclusive global rights to Hemgenix from gene therapy developers uniQure back in 2021.

article thumbnail

Why Mask-Associated Dry Eye Won’t Necessarily Boost Restasis Sales

XTalks

Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? This then leads to the development of a less-than-optimal tear film incapable of protecting the eye from further dryness.

Sales 119
article thumbnail

In the News: November Regulatory and Development Updates

Camargo

Camargo can help you to develop the right pricing and access strategy for your product; contact us for more information. A lesser-known provision also grants the same seven-year market exclusivity if the sponsor demonstrates that it does not expect to recover the development costs from selling the drug. Ken Phelps. Bill Stoltman, JD.